Group 1 - The company, Beijing Shali Bio-pharmaceutical Co., Ltd., has completed over 600 million C-round financing, led by Shunxi Fund with participation from multiple investors [2] - Established in 2019, the company focuses on tumor immune cell therapy, developing TIL drugs for pan-solid tumors and on-demand cell therapies [2] - The core R&D platforms include StemTexp® for TIL expansion, StaViral® for stable viral strains, ImmuT Finder® for immune target discovery, and KOReTIL® for efficient gene knockout [2] Group 2 - The company's self-developed GT101 injection is the first TIL drug approved for clinical registration in China and is currently in critical Phase II clinical trials [2] - The global first membrane-bound IL-15 complex TIL product, GT201 injection, has completed IND submissions in both China and the U.S. and has been approved for Phase I clinical trials [2] - The company has developed a range of innovative products, including a dual-gene knockout autologous TIL therapy, mRNA vaccines targeting tumor neoantigens, and a universal CAR-iNKT cell therapy derived from stem cells, forming a product matrix for pan-solid tumor TIL drugs and on-demand cell therapies [2]

Core Viewpoint - Company plans to invest in Beijing Shali Bio-pharmaceutical Co., Ltd. through its subsidiary, Shanghai JunTuo Bio-pharmaceutical Technology Co., Ltd., by subscribing to shares worth RMB 80 million, acquiring a 5.1105% stake in the target company [1][2] Group 1: Investment Details - JunTuo Bio intends to subscribe to 1,280,623 shares of Beijing Shali for RMB 80 million, while Shanghai TanYing Investment Partnership will invest RMB 40 million for 640,311 shares [1] - After the investment, the combined stake of the company and JunTuo Bio in Beijing Shali will be 5.1105% [1] Group 2: Target Company Overview - Beijing Shali is an innovative pharmaceutical company focused on tumor immune cell therapy, particularly developing tumor-infiltrating lymphocyte (TIL) drugs [1] - The company has developed GT101 injection, the first TIL drug approved for clinical registration in China, currently in critical Phase II clinical trials [1] - GT201 injection, the world's first membrane-bound IL-15 complex TIL product, has completed IND submissions in both China and the U.S. and is approved for Phase I clinical trials [1] Group 3: Strategic Rationale - The investment aligns with the company's long-term development strategy and is expected to enhance collaboration with other industry players, leveraging high-quality resources [2] - The transaction is not anticipated to adversely affect the company's normal operations or financial performance, benefiting the company and all shareholders [2]

Core Viewpoint - Junshi Biosciences (01877) is investing in Beijing Shali Bio-pharmaceutical Co., Ltd. through its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., by subscribing to shares worth RMB 80 million, acquiring a 5.1105% stake in the company [1][2] Group 1 - Junshi Biosciences' subsidiary plans to subscribe to 1,280,623 shares of Beijing Shali for RMB 80 million, while another shareholder, Shanghai Tanying Investment Partnership, will invest RMB 40 million for 640,311 shares [1] - Beijing Shali specializes in tumor immune cell therapy, focusing on tumor-infiltrating lymphocytes (TIL) and has developed the first TIL drug approved for clinical registration in China, GT101, which is currently in critical Phase II clinical trials [1] - The company has also completed dual IND submissions for its first membrane-bound IL-15 complex TIL product, GT201, which is approved to enter Phase I clinical trials [1] Group 2 - The investment is seen as a strategic move to enhance collaboration within the industry and leverage high-quality resources, aligning with the long-term development strategy of Junshi Biosciences [2] - The transaction is expected to have no significant adverse impact on the company's normal operations or financial performance, benefiting the company and all shareholders [2]